ACRX AcelRx Pharmaceuticals Inc.

3.2
-0.06  -2%
Previous Close 3.26
Open 3.24
Price To Book -5.25
Market Cap 198103270
Shares 61,907,272
Volume 3,861,954
Short Ratio
Av. Daily Volume 1,946,185

NewsSee all news

  1. AcelRx to announce fourth quarter 2018 results and provide a corporate update on Thursday, March 7th, 2019
  2. Biotech Leaders to Watch This Week
  3. 4 Healthcare Stocks Looking to Start Strong on Tuesday (2/19/19)
  4. Is AcelRx Pharmaceuticals (ACRX) Outperforming Other Medical Stocks This Year?
  5. AcelRx Pharmaceutical's sufentanil sublingual tablet (DSUVIA) to be highlighted during a presentation at the Boswick Burn and Wound Symposium

SEC filingsSee all SEC filings

  1. 8-K - Current report 19607077
  2. 8-K - Current report 19522597
  3. 8-K - Current report 181179155
  4. 424B5 - Prospectus [Rule 424(b)(5)] 181179103
  5. 424B5 - Prospectus [Rule 424(b)(5)] 181171317

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released August 15 2016
ARX-04 (SAP302)
Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury
FDA Approval announced November 2, 2018.
DSUVIA (ARX-04)
Moderate-to-severe acute pain following a surgical procedure
CRL Jul 26 2014. NDA resubmission timing being evaluated.
Zalviso
Post-operative pain following open abdominal surgery and hip or knee replacement surgery

Latest News

  1. AcelRx to announce fourth quarter 2018 results and provide a corporate update on Thursday, March 7th, 2019
  2. Biotech Leaders to Watch This Week
  3. 4 Healthcare Stocks Looking to Start Strong on Tuesday (2/19/19)
  4. Is AcelRx Pharmaceuticals (ACRX) Outperforming Other Medical Stocks This Year?
  5. AcelRx Pharmaceutical's sufentanil sublingual tablet (DSUVIA) to be highlighted during a presentation at the Boswick Burn and Wound Symposium
  6. Investor Expectations to Drive Momentum within PulteGroup, Dave & Buster's Entertainment, AcelRx Pharmaceuticals, LSC Communications, PNM Resources, Inc. (Holding Co.), and H&E Equipment Services — Discovering Underlying Factors of Influence
  7. AcelRx Pharmaceuticals announces publication analyzing pooled data on sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain
  8. 2 Biotech Penny Stocks to Buy Right Now
  9. Hedge Funds Are Crazy About AcelRx Pharmaceuticals Inc (ACRX)
  10. Implied Volatility Surging for AcelRx Pharmaceuticals (ACRX) Stock Options
  11. AcelRx Pharmaceuticals added to the NASDAQ Biotechnology Index (NBI)
  12. 3 Stocks to Hold for the Next 20 Years
  13. AcelRx Pharmaceuticals to Host Analyst and Investor Day on December 11
  14. New Healthcare Trends Could Push Sector Stocks Higher
  15. Edited Transcript of ACRX earnings conference call or presentation 5-Nov-18 1:30pm GMT
  16. AcelRx Pharmaceuticals to Present at the 17th Annual ASRA Pain Medicine Meeting
  17. Here's Why AcelRx Pharmaceuticals Lost as Much as 18.4% Today
  18. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
  19. AcelRx Pharmaceuticals Announces Proposed Public Offering of Common Stock

SEC Filings

  1. 8-K - Current report 19607077
  2. 8-K - Current report 19522597
  3. 8-K - Current report 181179155
  4. 424B5 - Prospectus [Rule 424(b)(5)] 181179103
  5. 424B5 - Prospectus [Rule 424(b)(5)] 181171317
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 181158971
  7. 8-K - Current report 181157171
  8. 8-K - Current report 181156718
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 18989533
  10. 8-K - Current report 18988240